文献速递神经肿瘤

先前接受一线化疗的少突胶质细胞瘤复发患者挽救治疗的有效性

The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy.
PubMed 文献 · World Neurosurg · 2018-03-16

本病例系列纳入28例新诊断的异柠檬酸脱氢酶突变且1p/19q共缺失的少突胶质细胞肿瘤患者,均接受一线丙卡巴肼、尼莫司汀和长春新碱治疗,回顾性分析临床结局与复发模式。中位随访90.2个月,15例(53.6%)出现疾病进展,其中14例(93.3%)为单纯局部复发,所有局部复发均行挽救治疗,首次进展后5年无进展生存率和总生存率分别为30.3%和92.9%。

要点

  • 15例进展患者中14例(93.3%)为单纯局部复发,所有局部复发均接受挽救治疗。
  • 首次进展后5年无进展生存率为30.3%,总生存率为92.9%。
  • 15例中9例(60%)目前无恶化,局部病灶控制或完全缓解;6例临床恶化,其中4例出现播散。

核心结论

  • 在异柠檬酸脱氢酶突变且1p/19q共缺失的少突胶质细胞瘤中,多数早期进展的肿瘤表现为局部、非致死性病灶,已被挽救治疗良好控制。
  • 使用分子参数对少突胶质细胞瘤进行精确诊断对于从挽救治疗中获得最佳获益至关重要。

研究设计与样本

  • 病例系列纳入28例新诊断的异柠檬酸脱氢酶突变且1p/19q共缺失的少突胶质细胞肿瘤患者,均接受一线丙卡巴肼、尼莫司汀和长春新碱治疗。
  • 回顾性分析临床结局和复发模式,中位随访期为90.2个月。

主要发现

  • 15例(53.6%)患者出现疾病进展,其中14例(93.3%)表现为单纯局部复发。
  • 所有局部复发均行挽救治疗,此后大多数后续进展也表现为可切除的局部复发。
  • 首次进展后5年无进展生存率为30.3%,总生存率为92.9%。
  • 15例中9例(60%)目前无恶化,局部病灶控制或完全缓解;6例观察到临床恶化,其中4例出现播散。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously reported a favorable outcome in a case series of patients with oligodendrogliomas treated with upfront chemotherapy; however, their progression-free survival (PFS) was relatively short considering their long-term overall survival (OS). This suggests that salvage treatments after progression were effective. However, the clinical impact of salvage treatments on outcomes of patients with recurrent oligodendrogliomas has not been precisely investigated. METHODS: Our case series included 28 patients with newly diagnosed isocitrate dehydrogenase-mutant and 1p/19q-codeleted oligodendroglial tumors treated with upfront procarbazine, nimustine, and vincristine. Clinical outcomes and patterns of recurrence were reviewed retrospectively. RESULTS: The median follow-up period of enrolled patients was 90.2 months. Disease progression occurred in 15 patients (53.6%), whereas the cancer appeared as local relapse alone in 14 (93.3%) patients. Salvage treatments were performed for all local relapses; thereafter, most of the subsequent progressions also appeared as resectable local relapses. The 5-year PFS and OS rates from the first progression were 30.3% and 92.9%, respectively. These relatively short PFS and favorable OS indicated the effectiveness of salvage treatment even after multiple progression. Thus far, 9 (60%) of 15 patients are deterioration-free with locally controlled lesions or complete remission; however, clinical deterioration was observed in 6 patients, and 4 of them experienced dissemination. CONCLUSIONS: In isocitrate dehydrogenase-mutant and 1p/19q-codeleted oligodendrogliomas, most of the tumors that demonstrated early progression appeared as local, nonlethal lesions, which have been well-controlled by salvage treatments. A precise diagnosis of oligodendrogliomas using molecular parameters is crucial to receive the best benefit from salvage treatment.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Kuga D, Hata N, Akagi Y, et al. The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy. World Neurosurg. 2018. PMID: 29551724. doi:10.1016/j.wneu.2018.03.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。